Understanding antibiotic resistance in patients with cystic fibrosis
A defective gene causes thick, sticky mucus to build up in the lungs of patients with cystic fibrosis (CF). There, it traps bacteria,...
#NACFC — Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study
Sound Pharmaceuticals (SPI) will present data on the incidence and severity of ototoxicity in cystic fibrosis (CF) patients who received...
MS1819-SD Shows Positive Results for Exocrine Pancreatic Insufficiency in Phase 2a Trial
AzurRx BioPharma, in partnership with Mayoly Spindler, announced that a recent Phase 2a clinical trial testing MS1819-SD as a potential...
Vertex and Treating CF: High Hopes for Triple Combinations and Gene Therapy Possibilities
Editor’s note: This is third in a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we look at...
Does Monotherapy With Correctors Have Clinical Benefit in Cystic Fibrosis?
Insufficient evidence exists to demonstrate that monotherapy with correctors has clinically important effects in individuals with cystic...
Dietary Flavonoids May Help in Managing CF Through Impact on Gut Bacteria, Small Study Suggests
Consuming dietary flavonoids — compounds naturally found in fruits, vegetables, chocolate, and beverages like wine and tea — may be...
Take the MECFA Survey!
Dear MECFA Members and Friends, The Middle East Cystic Fibrosis Association (MECFA) is non profit organization dedicated to improving...
Vertex and Treating CF: 3 Disease-modifying Therapies Make Leap from Lab to Patients
Editor’s Note: This is the second of a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. Here, we...
Discovering the ancient origin of cystic fibrosis, the most common genetic disease in Caucasians
Imagine the thrill of discovery when more than 10 years of research on the origin of a common genetic disease, cystic fibrosis (CF),...
Vertex and Treating CF: Stepping Out on Long Road to ‘Medical History’
Editor’s note: This is the first of a four-part series looking at Vertex Pharmaceuticals and its “all in for CF” approach. We begin by...
